Praised just recently as “hope for the unvaccinated world,” a Covid-19 vaccine developed by Germany’s CureVac is only 47% effective against the coronavirus. As its stock collapsed, the company blamed new virus variants.

Preliminary results from second and third-phase trials on 40,000 subjects in 10 countries of Europe and Latin America show that CureVac’s jab “did not meet pre-specified statistical success criteria,” the company announced on Wednesday.

“In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against [Covid]-19 disease of any severity,” the Tubingen-based company said.

“Initial analyses suggest age and strain dependent efficacy,” the company added, as its stock collapsed on the news of failure.

“While we were hoping for a stronger interim outcome, we recognize that demonstrating high efficacy in this unprecedented broad diversity of variants is challenging,” said CureVac CEO Dr. Franz-Werner Haas, adding that “the overall vaccine efficacy may change” as they continue towards the final analysis. (RT)